DNLI

Denali Therapeutics Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000

$18.94Close $3.0BMarket cap $14.41 – $27.2152-week range Nov 3, 2026Next report · after the close

Highlights

Cautions

Not in an uptrend 3 of 8 trend conditions
Lagging the market RS 33 · weaker than 67% of stocks over 12 months
Far from its high 30% below its 52-week high
Distribution down-day volume 2.1× up-day volume over 50 sessions
Results soon Nov 3, 2026, in 2 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 6, 2026

Off 12-month high 30%

1wk 2.9% price change

1mo 8.4% price change

12-month return 16% market up 11% · its own up 6%

F-score — — Not assessed

Altman Z 10.27 Low risk

P/E — price / earnings

PEG — P/E / EPS growth

P/B 2.9× price / book

Earnings yield 20.2% EBIT / enterprise value

Cheaper than 22% of the market · expensive

Revenue growth — year on year

EPS growth — latest quarter

Sales growth — latest quarter

ROE 46% return on equity

Free cash margin — -$422.1M FCF

D/E — long-term debt / equity

Net debt / EBITDA —

Interest cover —EBIT / interest

Trade setup

ATR% 4.1% $0.78 a day · 2×ATR $17.37

RS 33 / 99 vs the universe

Trend 3 / 8 trend template

Relative volume 0.8× vs 50-day average

Up/down volume 0.48 50 sessions

Implied move — no option chain · report Nov 3, 2026

Trend template · 3 of 8

Price above the 150 and 200-day averages: fails
150-day average above the 200-day: passes
200-day average rising for a month: passes
50-day average above the 150 and 200-day: fails
Price above the 50-day average: fails
At least 30% above the 52-week low: passes
Within 25% of the 52-week high: fails
RS rank 70 or higher: fails

Screen verdict

Did not qualify for any screen.

Warning signs

1 flagged

Shareholders diluted The share count rose 8.3% over the year, from 144m to 156m shares. Each existing share owns a smaller fraction of the company than it did a year ago.

Last reported Aug 6, 2026

Last shock Jul 14, 2026-14% in one session2.8× volumeno filing matched-16% since

Financials

6 fiscal years · from filings

Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $0

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$512.5M

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology -$422.1M

Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology

Net
Free cash

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 156.18m +29.6% since FY2020

	FY2020Dec 31, 2020	FY2021Dec 31, 2021	FY2022Dec 31, 2022	FY2023Dec 31, 2023	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Revenue	$335.6M	$48.7M	$105.1M	$330.5M	$0	$0
Operating income	$62.7M	-$295.8M	-$340.7M	-$196.7M	-$487.3M	-$555.3M
Net income	$71.1M	-$290.6M	-$326.0M	-$145.2M	-$422.8M	-$512.5M
Net margin	21%	-597%	-310%	-44%	—	—
Earnings per share	$0.63	-$2.39	-$2.60	-$1.06	-$2.57	-$2.97
Free cash flow	$413.1M	-$219.9M	-$262.5M	-$370.9M	-$363.6M	-$422.1M
Free cash margin	123%	-452%	-250%	-112%	—	—
Cash	$507.1M	$293.5M	$218.0M	$127.1M	$175.0M	$205.3M
Shareholders' equity	$1.2B	$962.3M	$1.0B	$1.0B	$1.2B	$1.0B
Shares outstanding	120.53m	122.28m	135.97m	138.39m	144.22m	156.18m

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Aug 6, 2026	Quarterly ↗	Jun 30, 2026	37d
May 7, 2026	Quarterly ↗	Mar 31, 2026	37d
Feb 26, 2026	Annual ↗	Dec 31, 2025	57d
Nov 6, 2025	Quarterly ↗	Sep 30, 2025	37d
Aug 11, 2025	Quarterly ↗	Jun 30, 2025	42d
May 6, 2025	Quarterly ↗	Mar 31, 2025	36d
Feb 27, 2025	Annual ↗	Dec 31, 2024	58d
Nov 6, 2024	Quarterly ↗	Sep 30, 2024	37d
Aug 1, 2024	Quarterly ↗	Jun 30, 2024	32d
May 7, 2024	Quarterly ↗	Mar 31, 2024	37d
Feb 28, 2024	Annual ↗	Dec 31, 2023	59d
Nov 7, 2023	Quarterly ↗	Sep 30, 2023	38d

Current reports

Filed	Disclosed
Aug 6, 2026	Results ↗
Jul 28, 2026	Acquisition or disposal ↗
Jun 18, 2026	Material agreement · Regulation FD ↗
Jun 4, 2026	Shareholder vote ↗
May 22, 2026	Regulation FD ↗
May 7, 2026	Results ↗
Apr 3, 2026	Agreement ended ↗
Mar 31, 2026	New obligation · Regulation FD ↗
Mar 25, 2026	Regulation FD ↗
Feb 26, 2026	Results ↗
Jan 6, 2026	Regulation FD ↗
Dec 10, 2025	Material agreement · Other events ↗